According to a recent risk stratification analysis of patients with AML, those harboring FLT3-ITD mutations exhibited a decreased likelihood of attaining complete remission and were at increased risk of disease relapse[21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.